{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T21:25:32Z","timestamp":1781299532393,"version":"3.54.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T00:00:00Z","timestamp":1711670400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T00:00:00Z","timestamp":1711670400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s11033-024-09431-7","type":"journal-article","created":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T17:01:35Z","timestamp":1711731695000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Ataxia telangiectasia and Rad3-related (ATR) inhibition by VE-822 potently reversed 5-flourouracil resistance in colorectal cancer cells through targeting DNA damage response"],"prefix":"10.1007","volume":"51","author":[{"given":"Ainaz","family":"Mihanfar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faezeh","family":"Asghari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Majidinia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,29]]},"reference":[{"issue":"3","key":"9431_CR1","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3322\/caac.21772","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A (2023) Colorectal cancer statistics, 2023. Cancer J Clin 73(3):233\u2013254","journal-title":"Cancer J Clin"},{"key":"9431_CR2","doi-asserted-by":"crossref","unstructured":"Kanth P, Inadomi JM (2021) Screening and prevention of colorectal cancer. BMJ. 374","DOI":"10.1136\/bmj.n1855"},{"issue":"4","key":"9431_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/or.2023.8612","volume":"50","author":"SM Alzahrani","year":"2023","unstructured":"Alzahrani SM, Al Doghaither HA, Al\u2013Ghafari AB, Pushparaj PN (2023) 5\u2013Fluorouracil and capecitabine therapies for the treatment of colorectal cancer. Oncol Rep 50(4):1\u201316","journal-title":"Oncol Rep"},{"key":"9431_CR4","doi-asserted-by":"publisher","first-page":"111285","DOI":"10.1016\/j.biopha.2021.111285","volume":"137","author":"C Sethy","year":"2021","unstructured":"Sethy C, Kundu CN (2021) 5-Fluorouracil (5-FU) resistance and the new strategy to enhance the sensitivity against cancer: implication of DNA repair inhibition. Biomed Pharmacother 137:111285","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"9431_CR5","doi-asserted-by":"publisher","first-page":"257","DOI":"10.20517\/cdr.2022.136","volume":"6","author":"WH Gmeiner","year":"2023","unstructured":"Gmeiner WH, Okechukwu CC (2023) Review of 5-FU resistance mechanisms in colorectal cancer: clinical significance of attenuated on-target effects. Cancer Drug Resist 6(2):257","journal-title":"Cancer Drug Resist"},{"issue":"4","key":"9431_CR6","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1111\/cbdd.14205","volume":"101","author":"R Shekh","year":"2023","unstructured":"Shekh R, Ahmad A, Tiwari RK, Saeed M, Shukla R, Al-Thubiani WS et al (2023) High therapeutic efficacy of 5\u2010Fluorouracil\u2010loaded exosomes against colon cancer cells. Chem Biol Drug Des 101(4):962\u2013976","journal-title":"Chem Biol Drug Des"},{"issue":"7","key":"9431_CR7","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1111\/eva.12994","volume":"13","author":"E Hansen","year":"2020","unstructured":"Hansen E, Read AF (2020) Cancer therapy: attempt cure or manage drug resistance? Evol Appl 13(7):1660\u20131672","journal-title":"Evol Appl"},{"issue":"34","key":"9431_CR8","doi-asserted-by":"publisher","first-page":"3834","DOI":"10.3748\/wjg.v24.i34.3834","volume":"24","author":"K Van der Jeught","year":"2018","unstructured":"Van der Jeught K, Xu H-C, Li Y-J, Lu X-B, Ji G (2018) Drug resistance and new therapies in colorectal cancer. World J Gastroenterol 24(34):3834","journal-title":"World J Gastroenterol"},{"issue":"01","key":"9431_CR9","first-page":"13","volume":"67","author":"M Majidinia","year":"2017","unstructured":"Majidinia M, Alizadeh E, Yousefi B, Akbarzadeh M, Mihanfar A, Rahmati-Yamchi M, Zarghami N (2017) Co-inhibition of notch and nf-\u03bab signaling pathway decreases proliferation through downregulating i\u03bab-\u03b1 and hes-1 expression in human ovarian cancer OVCAR-3 cells. Drug Res 67(01):13\u201319","journal-title":"Drug Res"},{"issue":"9","key":"9431_CR10","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.1111\/cas.14532","volume":"111","author":"S Blondy","year":"2020","unstructured":"Blondy S, David V, Verdier M, Mathonnet M, Perraud A, Christou N (2020) 5-Fluorouracil resistance mechanisms in colorectal cancer: from classical pathways to promising processes. Cancer Sci 111(9):3142\u20133154","journal-title":"Cancer Sci"},{"key":"9431_CR11","doi-asserted-by":"crossref","unstructured":"Majidinia M, Alizadeh E, Yousefi B, Akbarzadeh M, Zarghami N (2016) Downregulation of notch signaling pathway as an effective chemosensitizer for cancer treatment. Drug Res. :571\u2013579","DOI":"10.1055\/s-0042-111821"},{"key":"9431_CR12","doi-asserted-by":"publisher","first-page":"101084","DOI":"10.1016\/j.redox.2018.101084","volume":"25","author":"US Srinivas","year":"2019","unstructured":"Srinivas US, Tan BW, Vellayappan BA, Jeyasekharan AD (2019) ROS and the DNA damage response in cancer. Redox Biol 25:101084","journal-title":"Redox Biol"},{"key":"9431_CR13","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.dnarep.2019.06.005","volume":"80","author":"M Mirza-Aghazadeh-Attari","year":"2019","unstructured":"Mirza-Aghazadeh-Attari M, Ostadian C, Saei AA, Mihanfar A, Darband SG, Sadighparvar S et al (2019) DNA damage response and repair in ovarian cancer: potential targets for therapeutic strategies. DNA Repair 80:59\u201384","journal-title":"DNA Repair"},{"issue":"12","key":"9431_CR14","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1038\/s41580-019-0169-4","volume":"20","author":"H Lans","year":"2019","unstructured":"Lans H, Hoeijmakers JH, Vermeulen W, Marteijn JA (2019) The DNA damage response to transcription stress. Nat Rev Mol Cell Biol 20(12):766\u2013784","journal-title":"Nat Rev Mol Cell Biol"},{"key":"9431_CR15","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3389\/fmolb.2019.00061","volume":"6","author":"K Burger","year":"2019","unstructured":"Burger K, Ketley RF, Gullerova M (2019) Beyond the trinity of ATM, ATR, and DNA-PK: multiple kinases shape the DNA damage response in concert with RNA metabolism. Front Mol Biosci 6:61","journal-title":"Front Mol Biosci"},{"issue":"14","key":"9431_CR16","doi-asserted-by":"publisher","first-page":"11684","DOI":"10.3390\/ijms241411684","volume":"24","author":"H Biswas","year":"2023","unstructured":"Biswas H, Makinwa Y, Zou Y (2023) Novel Cellular functions of ATR for therapeutic targeting: embryogenesis to Tumorigenesis. Int J Mol Sci 24(14):11684","journal-title":"Int J Mol Sci"},{"issue":"2","key":"9431_CR17","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41568-022-00535-5","volume":"23","author":"FJ Groelly","year":"2023","unstructured":"Groelly FJ, Fawkes M, Dagg RA, Blackford AN, Tarsounas M (2023) Targeting DNA damage response pathways in cancer. Nat Rev Cancer 23(2):78\u201394","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"9431_CR18","first-page":"1307","volume":"8","author":"L-L Sun","year":"2018","unstructured":"Sun L-L, Yang R-Y, Li C-W, Chen M-K, Shao B, Hsu J-M et al (2018) Inhibition of ATR downregulates PD-L1 and sensitizes tumor cells to T cell-mediated killing. Am J cancer Res 8(7):1307","journal-title":"Am J cancer Res"},{"issue":"2","key":"9431_CR19","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1039\/C8CS00641E","volume":"48","author":"MR Gill","year":"2019","unstructured":"Gill MR, Vallis KA (2019) Transition metal compounds as cancer radiosensitizers. Chem Soc Rev 48(2):540\u2013557","journal-title":"Chem Soc Rev"},{"key":"9431_CR20","doi-asserted-by":"publisher","first-page":"114767","DOI":"10.1016\/j.bcp.2021.114767","volume":"193","author":"Q Yin","year":"2021","unstructured":"Yin Q, Liu X, Hu L, Song Q, Liu S, Huang Q et al (2021) VE-822, a novel DNA holliday junction stabilizer, inhibits homologous recombination repair and triggers DNA damage response in osteogenic sarcomas. Biochem Pharmacol 193:114767","journal-title":"Biochem Pharmacol"},{"issue":"12","key":"9431_CR21","doi-asserted-by":"publisher","first-page":"e441","DOI":"10.1038\/cddis.2012.181","volume":"3","author":"E Fokas","year":"2012","unstructured":"Fokas E, Prevo R, Pollard J, Reaper P, Charlton P, Cornelissen B et al (2012) Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation. Cell Death Dis 3(12):e441\u2013e","journal-title":"Cell Death Dis"},{"issue":"11","key":"9431_CR22","doi-asserted-by":"publisher","first-page":"3040","DOI":"10.1158\/0008-5472.CAN-16-3398","volume":"77","author":"A Schmitt","year":"2017","unstructured":"Schmitt A, Knittel G, Welcker D, Yang T-P, George J, Nowak M et al (2017) ATM Deficiency is Associated with sensitivity to PARP1-and ATR inhibitors in lung AdenocarcinomaTargeting DNA repair\u2013deficient lung adenocarcinomas. Cancer Res 77(11):3040\u20133056","journal-title":"Cancer Res"},{"key":"9431_CR23","doi-asserted-by":"publisher","first-page":"6083","DOI":"10.2147\/OTT.S211560","volume":"12","author":"X Liang","year":"2019","unstructured":"Liang X, Yang Q, Wang W, Liu T, Hu J (2019) VE-822 mediated inhibition of ATR signaling sensitizes chondrosarcoma to cisplatin via reversion of the DNA damage response. OncoTargets Therapy 12:6083","journal-title":"OncoTargets Therapy"},{"key":"9431_CR24","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.canlet.2018.06.010","volume":"432","author":"Q Shi","year":"2018","unstructured":"Shi Q, Shen L-Y, Dong B, Fu H, Kang X-Z, Yang Y-B et al (2018) The identification of the ATR inhibitor VE-822 as a therapeutic strategy for enhancing cisplatin chemosensitivity in esophageal squamous cell carcinoma. Cancer Lett 432:56\u201368","journal-title":"Cancer Lett"},{"issue":"10","key":"9431_CR25","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/nrc3599","volume":"13","author":"C Holohan","year":"2013","unstructured":"Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG (2013) Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 13(10):714\u2013726","journal-title":"Nat Rev Cancer"},{"key":"9431_CR26","doi-asserted-by":"crossref","unstructured":"Yousefi B, Zarghami N, Samadi N, Majidinia M (2016) Peroxisome proliferator-activated receptors and their ligands in cancer drug-resistance: opportunity or challenge. Anti-cancer agents in Medicinal Chemistry (formerly current Medicinal Chemistry-Anti-cancer agents). 16(12):1541\u20131548","DOI":"10.2174\/1871520616666160204112941"},{"issue":"8","key":"9431_CR27","first-page":"118","volume":"61","author":"B Yousefi","year":"2015","unstructured":"Yousefi B, Samadi N, Baradaran B, Rameshknia V, Shafiei-Irannejad V, Majidinia M et al (2015) Differential effects of peroxisome proliferator-activated receptor agonists on doxorubicin-resistant human myelogenous leukemia (K562\/DOX) cells. Cell Mol Biol 61(8):118\u2013122","journal-title":"Cell Mol Biol"},{"key":"9431_CR28","doi-asserted-by":"publisher","first-page":"114643","DOI":"10.1016\/j.biopha.2023.114643","volume":"162","author":"C Duan","year":"2023","unstructured":"Duan C, Yu M, Xu J, Li B-Y, Zhao Y, Kankala RK (2023) Overcoming Cancer Multi-drug Resistance (MDR): reasons, mechanisms, nanotherapeutic solutions, and challenges. Biomed Pharmacother 162:114643","journal-title":"Biomed Pharmacother"},{"issue":"9","key":"9431_CR29","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.3748\/wjg.v29.i9.1395","volume":"29","author":"S Al Bitar","year":"2023","unstructured":"Al Bitar S, El-Sabban M, Doughan S, Abou-Kheir W (2023) Molecular mechanisms targeting drug-resistance and metastasis in colorectal cancer: updates and beyond. World J Gastroenterol 29(9):1395","journal-title":"World J Gastroenterol"},{"issue":"12","key":"9431_CR30","doi-asserted-by":"publisher","first-page":"3683","DOI":"10.1158\/0008-5472.CAN-13-0110","volume":"73","author":"CJ Huntoon","year":"2013","unstructured":"Huntoon CJ, Flatten KS, Wahner Hendrickson AE, Huehls AM, Sutor SL, Kaufmann SH, Karnitz LM (2013) ATR inhibition broadly sensitizes ovarian Cancer cells to Chemotherapy Independent of BRCA StatusEffects of ATR versus Chk1 inhibition in Ovarian Cancer cells. Cancer Res 73(12):3683\u20133691","journal-title":"Cancer Res"},{"issue":"3","key":"9431_CR31","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.4143\/crt.2018.526","volume":"51","author":"A-R Nam","year":"2019","unstructured":"Nam A-R, Jin MH, Park JE, Bang J-H, Oh D-Y, Bang Y-J (2019) Therapeutic targeting of the DNA damage response using an ATR inhibitor in biliary tract cancer. Cancer Res Treatment: Official J Korean Cancer Association 51(3):1167\u20131179","journal-title":"Cancer Res Treatment: Official J Korean Cancer Association"},{"issue":"12","key":"9431_CR32","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1158\/1078-0432.CCR-16-2273","volume":"23","author":"H Kim","year":"2017","unstructured":"Kim H, George E, Ragland RL, Rafail S, Zhang R, Krepler C et al (2017) Targeting the ATR\/CHK1 Axis with PARP Inhibition results in Tumor regression in BRCA-Mutant ovarian Cancer ModelsATR\/CHK1 inhibition in combination with PARP inhibition. Clin Cancer Res 23(12):3097\u20133108","journal-title":"Clin Cancer Res"},{"issue":"25","key":"9431_CR33","doi-asserted-by":"publisher","first-page":"4869","DOI":"10.1038\/s41388-020-1328-y","volume":"39","author":"RL Lloyd","year":"2020","unstructured":"Lloyd RL, Wijnhoven PW, Ramos-Montoya A, Wilson Z, Illuzzi G, Falenta K et al (2020) Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells. Oncogene 39(25):4869\u20134883","journal-title":"Oncogene"},{"issue":"11","key":"9431_CR34","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1158\/0008-5472.CAN-18-2807","volume":"79","author":"E Comb\u00e8s","year":"2019","unstructured":"Comb\u00e8s E, Andrade AF, Tosi D, Michaud H-A, Coquel F, Garambois V et al (2019) Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (ATR) overcomes Oxaliplatin Resistance and promotes Antitumor Immunity in Colorectal CancerInhibition of ATR overcomes resistance to Oxaliplatin in CRC. Cancer Res 79(11):2933\u20132946","journal-title":"Cancer Res"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-024-09431-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-024-09431-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-024-09431-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T20:24:10Z","timestamp":1738700650000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-024-09431-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,29]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["9431"],"URL":"https:\/\/doi.org\/10.1007\/s11033-024-09431-7","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,29]]},"assertion":[{"value":"5 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"474"}}